Top

International Journal of Clinical Oncology

Published in:

01-06-2017 | Original Article

Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma

Authors: Takashi Suzuki, Hideaki Shimada, Tatsuki Nanami, Yoko Oshima, Satoshi Yajima, Naohiro Washizawa, Hironori Kaneko

Published in: International Journal of Clinical Oncology | Issue 3/2017

Abstract

Background

Preoperative hyperfibrinogenemia is associated with inflammatory mediators and a poor prognosis in several types of cancer. However, there is no published information on the monitoring of patients with preoperative hyperfibrinogenemia after surgery. The aim of the study reported here was to assess the clinicopathological and prognostic significance of plasma fibrinogen levels in patients with esophageal squamous cell carcinoma before and after surgical treatment.

Methods

Plasma fibrinogen levels were analyzed before surgical treatment (endoscopic submucosal dissection and surgery) in 82 patients with esophageal squamous cell carcinoma. The clinicopathological significance of plasma fibrinogen levels and the relationship of plasma fibrinogen levels with several biomarkers were evaluated. The cutoff value for hyperfibrinogenemia was 321 mg/dl. Univariate and multivariate analysis using the Cox proportional hazards model were performed to evaluate the prognostic significance of plasma fibrinogen levels. The changing patterns of plasma fibrinogen were monitored after surgical treatment to evaluate prognostic impact.

Results

Hyperfibrinogenemia was significantly associated with advanced pathological stage of cancer and high C-reactive protein levels. Plasma fibrinogen levels significantly decreased after surgical treatment in recurrence-free patients but did not decrease in patients with recurrence. The multivariate analysis indicated that preoperative hyperfibrinogenemia was an independent prognostic factor for poor survival (hazard ratio 1.005, 95% confidence interval 1.000–1.010; P = 0.039).

Conclusion

Preoperative hyperfibrinogenemia was associated with inflammatory mediators, tumor progression, and poor survival in patients with esophageal squamous cell carcinoma. The absence of a decrease in plasma fibrinogen levels after surgical treatment may indicate the possibility of tumor recurrence.

Suzuki T, Shimada H, Nanami T et al (2016) Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer. Surg Today. 46(12):1394–1401. doi:10.1007/s00595-016-1339-z

Qi Q, Geng Y, Sun M et al (2015) Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in advanced pancreatic cancer. Pancreas 44:977–982CrossRefPubMed

Kinoshita A, Onoda H, Imai N et al (2013) Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma. Oncology 85:269–277CrossRefPubMed

Son HJ, Park JW, Chang HJ et al (2013) Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 20:2908–2913CrossRefPubMed

Du J, Zheng JH, Chen XS et al (2013) High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma. Int J Clin Oncol 18:517–523CrossRefPubMed

Rickles FR, Hancock WW, Edwards RL et al (1988) Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 14:88–94CrossRefPubMed

Hogg N (1983) Human monocytes have prothrombin cleaving activity. Clin Exp Immunol 53:725–730PubMedPubMedCentral

Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349:13–15CrossRef

Arigami T, Okumura H, Matsumoto M et al (2015) Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis. Medicine (Baltimore) 94:e1702CrossRefPubMedPubMedCentral

10.

Li XH, Wang XP, Gu WS et al (2015) Clinical significance of preoperative thrombin time in patients with esophageal squamous cell carcinoma following surgical resection. PLoS One 10:e0140323CrossRefPubMedPubMedCentral

11.

Takeuchi H, Ikeuchi S, Kitagawa Y et al (2007) Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 22:2222–2227CrossRefPubMed

12.

Matsuda S, Takeuchi H, Fukuda K et al (2013) Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patient receiving neoadjuvant treatment. Dis Esophagus 27:654–661CrossRefPubMed

13.

Tian R, Yan H, Zhang F et al (2016) Cumulative score based on preoperative plasma fibrinogen and serum C-reactive protein could predict long-term survival for esophageal squamous cell carcinoma. Oncotarget. 7(38):61533–61543. doi:10.18632/oncotarget.11145

14.

Wang J, Liu H, Shao N et al (2015) The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma. World J Surg Oncol 13:157CrossRefPubMedPubMedCentral

15.

Zhang D, Zhou X, Bao W et al (2015) Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma. Oncotarget 6:38410–38420PubMedPubMedCentral

16.

Zhang SS, Lei YY, Cai XL et al (2016) Preoperative serum fibrinogen is an independent prognostic factor in operable esophageal cancer. Oncotarget 7:25461–25469PubMedPubMedCentral

17.

The Japan Esophageal Society (2015) Japanese classification of esophageal carcinoma (2015), 11th English edn. The Japan Esophageal Society, Tokyo

18.

SEKISUI Medical Co., Ltd.http://www.sekisuimedical.jp/english/business/diagnostics/blood/fbg/index.html

19.

Kanai M, Okumura N, Tozuka M et al (2015) Ketsueki Gyoko Inshi Teiryo (in Japanese) Rinshou Kensahou Teiyou. Kanehara. pp 402–403

20.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458CrossRef

21.

Hu C, Chen R, Chen W et al (2014) Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer. Exp Ther Med 8:125–132PubMedPubMedCentral

22.

Zhao L, Feng S, Huang S et al (2015) Diagnostic value of hyperfibrinogenemia as a predictive factor for appendiceal perforation in acute appendicitis. ANZ J Surg. doi:10.1111/ans.13316

23.

Yu X, Hu F, Yao Q et al (2016) Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study. BMC Cancer 16:480. doi:10.1186/s12885-016-2510-z CrossRefPubMedPubMedCentral

24.

Yamashita H, Kitayama J, Nagawa H et al (2005) Hyperfirinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 35:595–600CrossRefPubMed

Title: Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma
Authors: Takashi Suzuki
Hideaki Shimada
Tatsuki Nanami
Yoko Oshima
Satoshi Yajima
Naohiro Washizawa
Hironori Kaneko
Publication date: 01-06-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1087-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer

Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions

Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma

Retrospective analysis of lung cancer patients treated with supportive care alone

Survival impact of local extension sites in surgically treated patients with temporal bone squamous cell carcinoma

Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer